The Insitute for Clinical and Economic Review (ICER) released an evidence report on cystic fibrosis treatments.
ICER evaluated Vertex Pharmaceuticals’ Trikafta, and examined new data on the following drugs from the same company: Kalydeco, Orkambi and Symdeko.
“CF is a devastating disease that affects the lungs and other organ systems, typically requires substantial medical care, and robs patients and families of hours each day, before taking away full years of life,” ICER CMO David Rind said in a statement. “Kalydeco was a great advance for a small segment of the CF population, and Trikafta appears to be an even more remarkable advance for a much larger segment of the population. Trikafta is likely to alter the course of disease for the majority of patients with CF, transforming their lives and the lives of caregivers. It is critical that all eligible patients be able to access CFTR modulators.”
To read the full press release, click here.